ÂÜŔňÂŇÂ×

Dr. Sal Salamone is the founder of Saladax Biomedical which is a company dedicated to the development of Therapeutic Drug Management (TDM) assays in the field of oncology and companion diagnostics. Saladax has launched numerous TDM oncology drug assays and supported clinical studies on their effective use. Dr. Salamone has more than 30 years’ experience in the health care and medical device industries. Prior to founding Saladax he was Senior Vice President of R&D at Orasure Technologies where he developed rapid point of care tests in the infectious disease and drugs of abuse areas. Before Orasure he was Vice President of Research and Development at Roche Diagnostics, where he was responsible for North American research and development efforts for the Laboratory Systems Division. Dr. Salamone’s efforts during his 17-year tenure at Roche resulted in the launch of seven major reagent product lines, comprised of more than 70 FDA approved products and more than 200 instrument applications. Dr. Salamone is well published in the field with more than 70 peer-reviewed publications, numerous book chapters and is also the holder of 42 issued US patents. He serves on the boards of several companies, is a reviewer for several scientific journals, participates on NIH study sections for SBIR-STTR grants and often is an invited speaker at major conferences. Dr. Salamone received two bachelor’s degrees from Villanova University, a master’s and a Ph.D. degree from Rutgers University and was a SERC Post-Doctoral Fellow at Oxford University.